The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Antibody Response to the BNT162b2 mRNA COVID-19 Vaccine in Subjects with Prior SARS-CoV-2 Infection
Open accessAbstract
Although antibody levels progressively decrease following SARS-CoV-2 infection, the immune memory persists for months. Thus, individuals who naturally contracted SARS-CoV-2 are expected to develop a more rapid and sustained response to COVID-19 vaccines than naïve individuals. In this study, we analyzed the dynamics of the antibody response to the BNT162b2 mRNA COVID-19 vaccine in six healthcare workers who contracted SARS-CoV-2 in March 2020, in comparison to nine control subjects without a previous infection. The vaccine was well tolerated by both groups, with no significant difference in the frequency of vaccine-associated side effects, with the exception of local pain, which was more common in previously infected subjects. Overall, the titers of neutralizing antibodies were markedly higher in response to the vaccine than after natural infection. In all subjects with pre-existing immunity, a rapid increase in anti-spike receptor-binding domain (RBD) IgG antibodies and neutralizing antibody titers was observed one week after the first dose, which seemed to act as a booster. Notably, in previously infected individuals, neutralizing antibody titers 7 days after the first vaccine dose were not significantly different from those observed in naïve subjects 7 days after the second vaccine dose. These results suggest that, in previously infected people, a single dose of the vaccine might be sufficient to induce an effective response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection.
Dan, J. M., Mateus, J., Kato, Y., Hastie, K. M., Yu, E. D., Faliti, C. E., Grifoni, A., Ramirez, S. I., Haupt, S., Frazier, A., et al. (2021) · Science · doi:10.1126/science.abf4063 · Cited by 2,656 · cited 2×
“The rapid and robust neutralizing antibody response to vaccination in these subjects confirms the persistence of the immunological memory of SARS-CoV-2 [5].”
BackgroundEvolution of antibody immunity to SARS-CoV-2
Gaebler, C., Wang, Z., Lorenzi, J. C. C., Muecksch, F., Finkin, S., Tokuyama, M., Cho, A., Jankovic, M., Schaefer-Babajew, D., Oliveira, T. Y., et al. (2021) · Nature · doi:10.1038/s41586-021-03207-w · Cited by 1,674
mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection
Stamatatos, L., Czartoski, J., Wan, Y.-H., Homad, L. J., Rubin, V., Glantz, H., Neradilek, M., Seydoux, E., Jennewein, M. F., MacCamy, A. J., et al. (2021) · Science · doi:10.1126/science.abg9175 · Cited by 557
Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals
Manisty, C., Otter, A. D., Treibel, T. A., McKnight, Á., Altmann, D. M., Brooks, T., Noursadeghi, M., Boyton, R. J., Semper, A., & Moon, J. C. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00501-8 · Cited by 369
Saadat, S., Rikhtegaran Tehrani, Z., Logue, J., Newman, M., Frieman, M. B., Harris, A. D., & Sajadi, M. M. (2021) · JAMA · doi:10.1001/jama.2021.3341 · Cited by 364
Prendecki, M., Clarke, C., Brown, J., Cox, A., Gleeson, S., Guckian, M., Randell, P., Pria, A. D., Lightstone, L., Xu, X.-N., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00502-x · Cited by 271 · cited 2×
“These results are in agreement with a recent study, which showed that a single BNT162b2 vaccine dose induced low-level neutralizing antibodies and T-cell responses in naïve individuals [10].”
BackgroundResultAbu Jabal, K., Ben-Amram, H., Beiruti, K., Batheesh, Y., Sussan, C., Zarka, S., & Edelstein, M. (2021) · Eurosurveillance · doi:10.2807/1560-7917.es.2021.26.6.2100096 · Cited by 271
Tada, T., Dcosta, B. M., Samanovic-Golden, M., Herati, R. S., Cornelius, A., Mulligan, M. J., & Landau, N. R. (2021) · doi:10.1101/2021.02.05.430003 · Cited by 153
Krammer, F., Srivastava, K., the PARIS team, & Simon, V. (2021) · doi:10.1101/2021.01.29.21250653 · Cited by 116
Metadata
- Authors
- Gobbi, F., Buonfrate, D., Moro, L., Rodari, P., Piubelli, C., Caldrer, S., Riccetti, S., Sinigaglia, A., & Barzon, L.
- Venue
- Viruses
- Publisher
- MDPI AG
- Published
- 2021-03-05
- Volume
- 13
- Issue
- 3
- Pages
- 422
- ISSN
- 1999-4915 (ISSN-L)
- OpenAlex
- W3133659396
- Cited by
- 178
- References
- 9
- FWCI
- 12.44
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antibody Response to the BNT162b2 mRNA COVID-19 Vaccine in Subjects with Prior SARS-CoV-2 Infection. https://app.cochat.ai/papers/10.3390/v13030422
- The paper
- Gobbi, F., Buonfrate, D., Moro, L., Rodari, P., Piubelli, C., Caldrer, S., Riccetti, S., Sinigaglia, A., & Barzon, L. (2021). Antibody Response to the BNT162b2 mRNA COVID-19 Vaccine in Subjects with Prior SARS-CoV-2 Infection. Viruses. https://doi.org/10.3390/v13030422
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.